Median’s therapeutic innovations and medical technologies will help save the lives of many patients in the future.

Dear clients and partners,

In 2020, Median Technologies achieved several decisive milestones against the backdrop of a major health crisis.

The performance recorded quarter after quarter by our iCRO business allowed us to post record turnover growth of + 51% for 2020 to 13.5 million euros. With an order backlog of over 51 million euros at the end of 2020, we anticipate a sustained level of activity for iCRO in the future.

The 35 million euro financing granted by the European Investment Bank (EIB) at the end of 2019 now supports our investment in the development of our iBiopsy® platform, which offers diagnostic and prognostic solutions non-invasively from medical images. iBiopsy® uses the most advanced artificial intelligence technologies combined with our expertise in data science and medical image processing and is the heart of Median’s innovation.

In March 2020, the signing of a first strategic partnership with AP-HP for the use of iBiopsy® in several clinical indications opened up broad opportunities for us to validate the relevance of our technologies. Two studies in liver cancer are underway today. Preliminary results have been published on the assessment of the risk of recurrence in patients with primary liver cancer, on the assessment of the anti-tumor immune response and more recently, on the assessment of liver fibrosis severity in NASH patients.

These initial results are essential for the next validation steps in larger cohorts of patients, which will be carried out principally through new clinical and industrial partnerships.

The positive progress that characterized 2020 continued into the start of this year with new iBiopsy® announcements. A few weeks ago, we signed a major research partnership with the University of California San Diego ; this collaboration will allow us to work on a cohort of more than 300 patients as part of our clinical development plan in NASH. At the same time, our position in imaging biomarkers has been enhanced by a new development plan named LCS (Lung Cancer Screening) in lung cancer, the leading cause of cancer death in the world.

Giving meaning to innovation is the first of our four corporate values. Every day, our teams are proud to contribute to the advancement of medical technologies and development of new therapies, particularly in the field of oncology. These therapeutic innovations and medical technologies will help save the lives of many patients in the future.

Thank you for supporting our work.

Fredrik Brag
CEO